Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2A1 | Q16548 | 1/20 | 0.46 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 6/20 | 0.42 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | KIF11 | P52732 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23231040 | 1.00 | BCL2A1 (0.46) | BCL2A1TEAD1MAOBKDM1ASLC6A2 | |
| SCHEMBL9913841 | 1.00 | BCL2A1 (0.46) | BCL2A1TEAD1MAOBKDM1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL9276249 | 0.98 | BCL2A1 (0.46) | BCL2A1TEAD1MAOBKDM1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL9276244 | 0.98 | BCL2A1 (0.46) | BCL2A1TEAD1MAOBKDM1ASLC6A2 | |
| SCHEMBL23206925 | 0.88 | BCL2A1 (0.58) | BCL2A1TEAD1MAOBKDM1ASLC6A2 | |
| SCHEMBL23230941 | 0.88 | BCL2A1 (0.58) | BCL2A1TEAD1MAOBKDM1ASLC6A2 | |
| Hydrochloric Acid SCHEMBL23167122 | 0.86 | BCL2A1 (0.57) | BCL2A1TEAD1MAOBKDM1ASLC6A2 | |
| SCHEMBL18186078 | 0.85 | BCL2A1 (0.53) | BCL2A1TEAD1MAOBKDM1ASLC6A2 | |
| SCHEMBL18186080 | 0.85 | BCL2A1 (0.53) | BCL2A1TEAD1MAOBKDM1ASLC6A2 | |
| SCHEMBL18186081 | 0.85 | BCL2A1 (0.53) | BCL2A1TEAD1MAOBKDM1ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076272-A1 | Activators of Heme Regulated Inhibitor Kinase (HRI) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2024-03-07 | — | — | US | disclosed |
| EP-4313951-A1 | 1,3-SUBSTITUTED CYCLOBUTYL DERIVATIVES AND USES THEREOF | Novartis AG (CH) | 2024-02-07 | — | — | EP | disclosed |
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2023-12-19 | — | — | US | disclosed |
| WO-2021072028-A1 | ACTIVATORS OF HEME REGULATED INHIBITOR KINASE (HRI) | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-04-15 | — | — | WO | disclosed |
| WO-2012072512-A1 | N-CYCLOBUTYL-IMIDAZOPYRIDINE OR -PYRAZOLOPYRIDINE CARBOXAMIDES AS TRPV1 ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845730-B2 | 1,3-substituted cyclobutyl derivatives and uses thereof | TRPV1, TRPV3, TRPV2 | BCL2A1 1531/4885TEAD1 2972/4885MAOB 1310/4885 |
| US-20240076272-A1 | Activators of Heme Regulated Inhibitor Kinase (HRI) | EEF2K, ATF4, EIF2AK4 | BCL2A1 1872/4885TEAD1 1304/4885MAOB 4058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.